97170 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TRANSPLANT REJECTION
#2CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE
#3IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE
#4LIPID PARTICLES COMPRISING VARIANT PARAMYXOVIRUS ATTACHMENT GLYCOPROTEINS AND USES THEREOF
#5Reagents for Directed Biomarker Signal Amplification
#6METHOD FOR IDENTIFYING NEOANTIGENS ON CANCER CELLS BY USING XENOANTIBODIES
#7Compositions and Methods for Inhibiting T Cell Exhaustion
#8CD4-SPECIFIC ANTIBODY CONSTRUCTS AND COMPOSITIONS AND USES THEREOF
#9METHODS TO IMPROVE STABILITY OF VIRUS TRANSDUCTION OF y8 T CELLS AND APPLICATIONS THEREOF
#10SYNCITIN-1 FUSION PROTEINS AND USES THEREOF FOR CARGO DELIVERY INTO TARGET CELLS
#11Antibodies Binding to Vista at Acidic pH
#12ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents
#13METHODS FOR IN VIVO EXPANSION OF CD8+ T CELLS AND PREVENTION OR TREATMENT OF GVHD
#14RETROVIRAL-LIKE PARTICLE-REDUCED CHINESE HAMSTER OVARY PRODUCTION CELL LINES
#15USE OF IMMUNOSUPPRESSION TO ENABLE ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS
#16HIGH-BRIGHTNESS FLUOROPHORES
#17Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#18MODIFIED PARAMYXOVIRIDAE ATTACHMENT GLYCOPROTEINS
#19SELECTIVE IMMUNODEPLETION OF ENDOGENOUS STEM CELL NICHE FOR ENGRAFTMENT
#20GENE SEQUENCE CONSTRUCT FOR GENE THERAPY OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION
#21ANTICANCER T CELL THERAPY PRODUCT-ASSISTING COMPOSITION COMPRISING DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY AND USE THEREOF
#22USE OF CD4-TARGETED VIRAL VECTORS
#23PD-1 single domain antibodies and therapeutic compositions thereof
#24RETARGETED RETROVIRAL VECTORS AND COMPOSITIONS OR METHODS OF USE THEREOF
#25Reagents for directed biomarker signal amplification
#26ATP-dependent agonists of immune cells function as anticancer agents
#27ANTIGEN BINDING POLYPEPTIDES
#28IMMUNE CELL PROLIFERATION/ACTIVATION KIT AND IMMUNE CELL CULTURE METHOD USING SAME PROLIFERATION/ACTIVATION KIT
#29NOVEL SINGLE DOMAIN ANTIGEN BINDING MOLECULES AND THEIR USES
#30CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS
#31CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
#32CHIMERIC ANTIGEN RECEPTORS (CARs) TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOF
#33THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE
#34Antibodies binding to VISTA at acidic pH
#35METHODS FOR SENSITIZING CANCER CELLS TO T CELL-MEDIATED KILLING BY MODULATING MOLECULAR PATHWAYS
#36METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION
#37METHOD FOR IDENTIFYING NEOANTIGENS ON CANCER CELLS BY USING XENOANTIBODIES
#38ANTI-DPP6 CHIMERIC ANTIGEN RECEPTOR BEARING REGULATORY T CELLS
#39IMMUNOLOGICAL BIOMARKER FOR PREDICTING CLINICAL EFFECT OF CANCER IMMUNOTHERAPY
#40METHODS FOR SELECTIVELY MODULATING THE ACTIVITY OF DISTINCT SUBTYPES OF CELLS
#41CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
#42MODULAR PLATFORM FOR TARGETED THERAPEUTICS
#43Reagents for directed biomarker signal amplification
#44COMPOSITIONS AND METHODS FOR PERFORMING MAGNETIBUOYANT SEPARATIONS
#45ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION
#46Reagents for directed biomarker signal amplification
#47Reagents for directed biomarker signal amplification
#48Selective immunodepletion of endogenous stem cell niche for engraftment
#49SOURCE SPECIFIC EXOSOMES FOR DETERMINING AVOIDANCE OF CANCER TREATMENT AND AVOIDANCE OF CHECKPOINT INHIBITOR THERAPIES
#50Compositions and Methods for Inhibiting T Cell Exhaustion
#51RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF
#52COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF
#53BISPECIFIC PROTEIN
#54METHODS OF TREATING CANCER
#55NOVEL ANTI-CD4 ANTIBODIES
#56DELAYING PEAK EFFECT AND/OR EXTENDING DURATION OF RESPONSE
#57Reagents for Directed Biomarker Signal Amplification
#58Reagents for directed biomarker signal amplification
#59Reagents for directed biomarker signal amplification
#60METHODS AND COMPOSITIONS FOR TARGETING TGF-ß SIGNALING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY
#61ANTI-CD33 ANTIBODIES FOR TREATING CANCER
#62BISPECIFIC NANOBODIES
#63C3D CELLULAR AND ACELLULAR VACCINES FOR THE PREVENTION AND TREATMENT OF CANCER
#64Reagents for directed biomarker signal amplification
#65HIGH-BRIGHTNESS NANODOT FLUOROPHORES BY COVALENT FUNCTIONALIZATION
#66MEDICAMENT AND METHOD FOR TREATING INFECTIOUS DISEASES
#67COMPOSITIONS AND METHODS FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS
#68SYNERGISTIC TUMOR TREATMENT WITH IL-2 AND INTEGRIN-BINDING-FC FUSION PROTEIN
#69Immunological biomarker for predicting clinical effect of cancer
#70POTENCY ASSAYS FOR ANTIBODY DRUG SUBSTANCE BINDING TO AN FC RECEPTOR
#71PD-1 single domain antibodies and therapeutic compositions thereof
#72Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII
#73USE OF AN ANTI-CD45 ANTIBODY DRUG CONJUGATE (ADC) IN CELL THERAPY
#74IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE
#75Nanolipogel vehicles for controlled delivery of different pharmaceutical agents
#76REDUCED AND MINIMAL MANIPULATION MANUFACTURING OF GENETICALLY-MODIFIED CELLS
#77CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY
#78Virtual assistant focused user interfaces
#79ANTIGEN BINDING CONSTRUCTS TO CD4
#80TARGETED LIPID PARTICLES AND COMPOSITIONS AND USES THEREOF
#81CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF
#82CO-RECEPTOR SYSTEMS FOR TREATING INFECTIOUS DISEASES
#83ANTIBODY TUMOR-TARGETING ASSEMBLY COMPLEXES
#84TREATMENT OF DISEASE VIA TRANSCRIPTION FACTOR MODULATION
#85APOPTOTIC CELL-MEDIATED INDUCTION OF ANTIGEN SPECIFIC REGULATORY T-CELLS FOR THE THERAPY OF AUTOIMMUNE DISEASES IN ANIMALS AND HUMANS
#86ANTICANCER T CELL THERAPY PRODUCT-ASSISTING COMPOSITION COMPRISING DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY AND USE THEREOF
#87ANTIBODY-MODIFIED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL AND USES THEREOF
#88Method for treatment of a leukocyte related disease by delivery of nucleic acid molecules to leukocytes using targeted lipid particles
#89Bispecific HIV-1-neutralizing antibodies
#90Engineering pH-dependent antigen binding activity into anti-HIV antibodies with improved pharmacokinetics
#91Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
#92Carbopyronone Compounds Useful as Diagnostic Adjuvants
#93Reagents for directed biomarker signal amplification
#94Bispecific molecules comprising an HIV-1 envelope targeting arm
#95MODULATION OF T CELLS WITH BISPECIFIC ANTIBODIES AND FC FUSIONS
#96T cells surface-loaded with immunostimulatory fusion molecules and uses thereof
#97METHODS FOR REDUCING VIRAL LOAD IN HIV-1 INFECTED PATIENTS
#98PREVENTION AND TREATMENT OF GVHD AND AUTOIMMUNE DISEASES
#99APOPTOTIC CELL-MEDIATED INDUCTION OF ANTIGEN SPECIFIC REGULATORY T-CELLS FOR THE THERAPY OF AUTOIMMUNE DISEASES IN ANIMALS AND HUMANS
#100Chimeric antigen receptors (CARs), compositions and methods thereof
#101PD-1 single domain antibodies and therapeutic compositions thereof
#102Nanolipogel vehicles for controlled delivery of different pharmaceutical agents
#103Reagents for direct biomarker signal amplification
#104Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
#105Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#106Immunoparticles and methods of generating and using same
#107METHODS FOR IN VIVO EXPANSION OF CD8+ T CELLS AND PREVENTION OR TREATMENT OF GVHD
#108Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
#109Dendritic Cells as a Novel Delivery System for Immunotherapy
#110Antibodies binding to VISTA at acidic pH
#111Immunological biomarker for predicting clinical effect of cancer
#112Chimeric antigen receptors (CARs), compositions and methods thereof
#113Methods of treating cancer in a subject having elevated ICOS and/or T-bet levels of CD+4 cells by administering an ICOS agonist
#114ANTIBODY COMPOSITION-PRODUCING CELL
#115Reagents for directed biomarker signal amplification
#116CHIMERIC ANTIGEN RECEPTORS (CARs) TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOF
#117Synergistic tumor treatment with an extended pharmacokinetic IL-2 and integrin-binding-Fc fusion protein
#118Targeted pyrrolobenzodiazapine conjugates
#119Modular platform for targeted therapeutics
#120Reagents for directed biomarker signal amplification
#121Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
#122PREVENTION OF GRAFT REJECTION BY PRIOR USE OF MODIFIED GRAFTS
#123PROTEIN EXPRESSION FROM MULTIPLE NUCLEIC ACIDS
#124THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE
#125METHOD FOR IDENTIFYING NEOANTIGENS ON CANCER CELLS BY USING XENOANTIBODIES
#126Nanolipogel comprising a polymeric matrix and a lipid shell
#127Reagents for directed biomarker signal amplification
#128Reagents for directed biomarker signal amplification
#129Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients
#130Modulation of T cells with bispecific antibodies and Fc fusions
#131Compositions and methods for inhibiting T cell exhaustion
#132RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF
#133Nipah virus envelope glycoprotein pseudotyped lentivirus
#134C3D cellular and acellular vaccines for the prevention and treatment of cancer
#135HIV-1 vaccine
#136THERAPEUTIC AGENT FOR SOLID CANCER
#137Compositions and methods for performing magnetibuoyant separations
#138Nanobody dimers linked via C-terminally engineered cysteins
#139ANTI-LAG-3 ANTIBODIES
#140COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND MTOR INHIBITORS
#141Methods of identifying immune cells in PD-L1 positive tumor tissue
#142CHIMERIC ANTIGEN RECEPTORS AND ENHANCEMENT OF ANTI-TUMOR ACTIVITY
#143Nanoparticle-mediated delivery of cytokines for maintenance of the regulatory T cell phenotype
#144Modified chimeric receptors and related compositions and methods
#145Carbopyronone compounds useful as diagnostic adjuvants
#146SELECTIVE IMMUNODEPLETION OF ENDOGENOUS STEM CELL NICHE FOR ENGRAFTMENT
#147Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
#148HIGH-BRIGHTNESS FLUOROPHORES
#149Immunity enhancing agent for cancer by Allergin-1 antagonist
#150Bispecific HIV-1-neutralizing antibodies
#151Near infrared photoimmunotherapy (NIR-PIT) of suppressor cells to treat cancer
#152Nanolipogel vehicles for controlled delivery of different pharmaceutical agents
#153Methods of transplantation and disease treatment
#154CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
#155HIGH THROUGHPUT OPTIMIZATION OF CONTENT-LOADED NANOPARTICLES
#156Bispecific molecules comprising an HIV-1 envelope targeting arm
#157Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes
#158Reagents for directed biomarker signal amplification
#159Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
#160Reagents for directed biomarker signal amplification
#161Reagents for directed biomarker signal amplification
#162Chimeric antigen receptors (CARs), targeting hematologic malignancies, compositions and methods of use thereof
#163Anti CD4 antibodies to prevent in particular graft-versus-host-disease (GVHD)
#164Anti CD4 antibodies to prevent in particular graft-versus-host-disease (GvHD)
#165TREATMENT OF DISEASE VIA TRANSCRIPTION FACTOR MODULATION
#166One step phagocytosis-cell activation-cell death assay
#167Antibodies directed against CD4 for the treatment and functional cure of HIV
#168POTENCY ASSAYS FOR ANTIBODY DRUG SUBSTANCE BINDING TO AN FC RECEPTOR
#169TOLEROGENIC COMPOSITIONS AND METHODS
#170Coumarin dyes and conjugates thereof
#171Bispecific HIV-1 neutralizing antibodies
#172T-cell redirecting bispecific antibodies for treatment of disease
#173Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
#174Methods of treating inflammatory and autoimmune diseases and disorders
#175Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein
#176PROTEIN EXPRESSION FROM MULTIPLE NUCLEIC ACIDS
#177THERAPEUTIC AGENT FOR SOLID CANCER
#178Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#179Induction of immunotolerance to improve acceptance of tissue derived from pluripotent stem cells
#180Method for reducing side effects of immune checkpoint control agent
#181METHOD AND COMPOSITION FOR THE TREATMENT OF DISEASES CAUSED BY OR ASSOCIATED WITH HIV
#182Selective immunodepletion of endogenous stem cell niche for engraftment
#183Carbopyronone compounds useful as diagnostic adjuvants
#184Modulation of T cells with bispecific antibodies and FC fusions
#185T-cell redirecting bispecific antibodies for treatment of disease
#186Combination therapy with CD4 lymphocyte depletion and MTOR inhibitors
#187Glycan-modified anti-CD4 antibodies for HIV prevention and therapy
#188Reagents for directed biomarker signal amplification
#189Antibody composition-producing cell
#190Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#191Transgenic transchromosomal rodents for making human antibodies
#192BISPECIFIC NANOBODIES
#193HIV-1 vaccine
#194Anti-HIV domain antibodies and method of making and using same
#195T-cell redirecting bispecific antibodies for treatment of disease
#196Targeted pyrrolobenzodiazapine conjugates
#197THERAPEUTIC OR PROPHYLACTIC AGENT FOR IMMUNODEFICIENCY VIRUS INFECTION
#198LINKED IMMUNOTHERAPEUTIC AGONISTS THAT COSTIMULATE MULTIPLE PATHWAYS
#199Amino acid sequences directed against cellular receptors for viruses and bacteria
#200Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
#201Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#202GLYCAN-MODIFIED ANTI-CD4 ANTIBODIES FOR HIV PREVENTION AND THERAPY
#203Bispecific HIV-1 neutralizing antibodies
#204Antibody composition-producing cell
#205THERAPEUTIC STRATEGY FOR TREATING AUTOIMMUNE AND DEGENERATIVE DISEASES
#206Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors
#207NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF
#208COMBINATION PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING AND PREVENTING THE INFECTIOUS DISEASES
#209COMBINATION PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING AND PREVENTING THE INFECTIOUS DISEASES
#210Transgenic transchromosomal rodents for making human antibodies
#211Method and kit for determining-antibody sensitivity and clone cell strain
#212Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
#213Protein expression from multiple nucleic acids
#214Method for making multispecific antibodies having heteromultimeric and common components
#215Targeting regulatory T cells with heterodimeric proteins
#216Targeting regulatory T cells with heterodimeric proteins
#217Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
#218Humanized anti-CD4 antibody with immunosuppressive properties
#219IMMUNOTHERAPY OF B CELL MALIGNANCIES AND AUTOIMMUNE DISEASES USING UNCONJUGATED ANTIBODIES AND CONJUGATED ANTIBODIES AND ANTIBODY COMBINATIONS AND FUSION PROTEINS
#220Lipoparticles comprising proteins, methods of making, and using the same
#221T-cell redirecting bispecific antibodies for treatment of disease
#222Anti CD4 antibodies to prevent in particular graft-versus-host-disease (GvHD)
#223Real-time adaptive immune system and method
#224Methods for reducing viral load in HIV-1 infected patients
#225POTENT, STABLE AND NON-IMMUNOSUPPRESSIVE ANTI-CD4 ANTIBODIES
#226Anti-CD4 antibody
#227Expression of monoclonal antibodies in ciliate host cells
#228NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF
#229COMPOSITIONS AND METHODS USEFUL FOR REDUCING THE VISCOSITY OF PROTEIN-CONTAINING FORMULATIONS
#230Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
#231Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#232HETEROLOGOUS ANTIBODIES WHICH BIND HUMAN CD4
#233Targeted pyrrolobenzodiazapine conjugates
#234Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors
#235Enhanced animal cell growth using ultrasound
#236METHODS FOR ENHANCING THE EFFICACY OF IL-2 MEDIATED IMMUNE RESPONSES
#237Agents for treating disease
#238ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE
#239Method of inducing an antiviral immune response against HIV-1 utilizing chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics
#240Pharmaceutical composition and method of inhibiting of production or amplifying of elimination of P24 protein
#241Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
#242Method for the production of antibodies that bind to multiple membrane spanning proteins
#243METHOD TO INHIBIT AIRWAY HYPERRESPONSIVENESS USING AEROSOLIZED T CELL RECEPTOR ANTIBODIES
#244Fusion antibodies for HIV therapy
#245HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENOMICE
#246Increasing protein production by increasing ABC50 expression or activity
#247AGENT FOR SUPPRESSING REPLICATION OF HIV AND USE THEREOF
#248Immunological reconstitution promoter or prophylactic agent for infections each of which maintains graft-versus-tumor effect
#249Amino acid sequences directed against cellular receptors for viruses and bacteria
#250Bifunctional Griffithsin Analogs
#251Reagents for directed biomarker signal amplification
#252Reagents for directed biomarker signal amplification
#253Reagents for directed biomarker signal amplification
#254Antibody composition-producing cell
#255METHODS FOR PREDICTING DEVELOPMENT OF AUTO-IMMUNE DISEASES AND TREATMENT OF SAME
#256COMPOSITION FOR TREATING DISEASE
#257SPECIFIC DEPLETION OF CD4+ T CELLS
#258Anti-HIV domain antibodies and method of making and using same
#259Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody
#260Method for treating psoriasis
#261Method for treating psoriasis
#262Agent for treating disease
#263Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation
#264ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION
#265Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes
#266Compositions and methods of tolerizing a primate to an antigen
#267Transgenic trasnchromosomal rodents for making human antibodies
#268NON-GLYCOSYLATED RECOMBINANT MONOVALENT ANTIBODIES
#269HIV-1 envelope glycoprotein oligomer and methods of use
#270Anti-CD4 antibody
#271Heterologous antibodies which bind human CD4
#272Humanized anti-CD4 antibody with immunosuppressive properties
#273METHOD FOR EXTENDING THE HALF-LIFE OF EXOGENOUS OR ENDOGENOUS SOLUBLE MOLECULES
#274Method for the preparation of virus-like particles (VLPS) comprising heterologous multiple membrane spanning proteins
#275Protein expression from multiple nucleic acids
#276SELECTIVE IMMUNODEPLETION OF ENDOGENOUS STEM CELL NICHE FOR ENGRAFTMENT
#277CHO-K1 CELL LINE
#278Methods for reducing viral load in HIV-1 infected patients
#279Antibody Composition-Producing Cell
#280SUBSTRATE FOR BIOLOGICAL FLUID TREATMENT
#281Methods of Treating Autoimmune Diseases Using CD4 Antibodies
#282Potency assays for antibody drug substance binding to an Fc receptor
#283Therapy with CD4 binding peptides and radiation
#284Human antibodies derived from immunized xenomice
#285PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE
#286AUGMENTATION OF IMMUNE RESPONSE TO CANCER VACCINE
#287NOVEL MEMORY CTL INDUCTION POTENTIATOR
#288IMMUNOTHERAPY OF B CELL MALIGNANCIES AND AUTOIMMUNE DISEASES USING UNCONJUGATED ANTIBODIES AND CONJUGATED ANTIBODIES AND ANTIBODY COMBINATIONS AND FUSION PROTEINS
#289Cells with altered fucosylation and producing antibodies therefrom
#290RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY
#291Recombinant monovalent antibodies and methods for production thereof
#292RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY
#293Use of HIV envelope/CD4 complexes for the generation antibodies
#294Method for screening for an anti-CD4 antibody suitable for use in immunotherapy
#295Humanized anti-CD4 antibody with immunosuppressive properties
#296Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation
#297Glycoengineered, recombinant antibody
#298Fluorescence resonance energy transfer screening assay for the identification of HIV-1 envelope glycoprotein-medicated cell
#299Human antibodies derived from immunized xenomice
#300Specific Depletion of CD4+ T Cells